ArticleFrontiers in molecular biosciences2026
Unraveling role of arginine-NO metabolism by targeting HIF-1α signaling in mediating esophageal squamous cell carcinoma.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Due to the lack of specific biomarkers, patients with esophageal cancer are often diagnosed at an advanced stage, resulting in poor treatment outcomes. This study aims to identify potential diagnostic and therapeutic biomarkers for esophageal squamous cell carcinoma (ESCC) through metabolomics and to elucidate their mechanisms of action. Methods: Untargeted metabolomics was employed to analyze ESCC tissue samples and matched normal esophageal tissue samples. Differentially expressed metabolites were identified using multivariate statistical analysis. MetaboAnalyst 6.0 software was used for pathway analysis. Key molecules were validated via immunohistochemistry (IHC) and Western blot (WB), and their functions were assessed through cellular functional assays. Results: A total of 2,850 metabolites were identified, among which 939 were differentially regulated, including 575 upregulated and 364 downregulated metabolites. Pathway enrichment analysis revealed that these differentially expressed metabolites were predominantly enriched in amino acid metabolism-related pathways, Mechanistically, activation of the HIF-1α-iNOS-NO signaling axis drove arginine metabolic reprogramming, leading to profound metabolic disturbances that ultimately enhanced the migratory and invasive capacities of ESCC cells. Conclusion: This study confirms that ESCC exhibits significant amino acid metabolic dysregulation, with arginine related metabolic pathways being significantly enriched. This disruption in arginine metabolism may be caused by hypoxia, which activates the iNOS-NO signaling axis mediated by HIF-1α, thereby promoting the migratory and invasive capabilities of ESCC. Finally, the study confirmed that NO can serve as a potential non-invasive biomarker for distinguishing ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.